Agios sells rights to glioma drug to Royalty Pharma; Cargo’s $110M placement

Plus, news about Turn Biotechnologies, HanAll Biopharma, Corcept Therapeutics, Actuate and Merck:

Agios sells vorasidenib rights to Royalty Pharma: As part of the agreement, the …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Optimi Health Achieves Genetics Milestone and Completes Psilocybin Extract Validation and Stability Testing | Psychedelic Invest

Optimi Health Corp. (CSE: OPTI) (OTCQX: OPTHF) (FRA: 8BN), a leading end-to-end drug researcher and formulator licensed by Health Canada, has reached a significant milestone

November 29, 2023

Shasqi using click chemistry to target cancer

Shasqi, Inc., whose mission is to revolutionize cancer treatment with click chemistry, has entered into a research collaboration with Johnson & Johnson Enterprise Innovation Inc.

June 6, 2023

Pyroptosis: A potential therapeutic target for lung cancer

Lung cancer, one of the most aggressive forms of cancer, continues to be a leading cause of death worldwide. Although several new therapies have been

June 28, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.